HBV VIS Detail Information

> This page shows VIS [1018142] detail information, including site information (chromosome, GRCh38 location, disease, sample, etc) and literature information.

Site Information

DVID	1018142
VISID	TVIS10005249
Chromosome	chr14
GRCh38 Location	97592167
Disease	Hepatocellular carcinoma
Sample	Nontumor
Virus Reference Genome	AP011098

Literature Information

PubMed PMID	29861854
Published year	2018
Journal	Oncotarget
Title	Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers.
Author	Furuta M,Tanaka H,Shiraishi Y,Unida T,Imamura M,Fujimoto A,Fujita M,Sasaki-Oku A,Maejima K,Nakano K,Kawakami Y,Arihiro K,Aikata H,Ueno M,Hayami S,Ariizumi SI,Yamamoto M,Gotoh K,Ohdan H,Yamaue H,Miyano S,Chayama K,Nakagawa H
Evidence	Integration of Hepatitis B virus (HBV) into the human genome can cause genetic instability, leading to selective advantages for HBV-induced liver cancer. Despite the large number of studies for HBV integration into liver cancer, little is known about the mechanism of initial HBV integration events owing to the limitations of materials and detection methods. We conducted an HBV sequence capture, followed by ultra-deep sequencing, to screen for HBV integrations in 111 liver samples from human-hepatocyte chimeric mice with HBV infection and human clinical samples containing 42 paired samples from non-tumorous and tumorous liver tissues. The HBV infection model using chimeric mice verified the efficiency of our HBV-capture analysis and demonstrated that HBV integration could occur 23 to 49 days after HBV infection via microhomology-mediated end joining and predominantly in mitochondrial DNA. Overall HBV integration sites in clinical samples were significantly enriched in regions annotated as exhibiting open chromatin, a high level of gene expression, and early replication timing in liver cells. These data indicate that HBV integration in liver tissue was biased according to chromatin accessibility, with additional selection pressures in the gene promoters of tumor samples. Moreover, an integrative analysis using paired non-tumorous and tumorous samples and HBV-related transcriptional change revealed the involvement of TERT and MLL4 in clonal selection. We also found frequent and non-tumorous liver-specific HBV integrations in FN1 and HBV-FN1 fusion transcript. Extensive survey of HBV integrations facilitates and improves the understanding of the timing and biology of HBV integration during infection and HBV-related hepatocarcinogenesis.